Sanderling Renal Services, headquartered in Nashville, Tennessee, has purchased 10 Redsense devices for one of their Nashville facilities. Sanderling is a US dialysis provider with a nation-wide network of clinics.
"Sanderling Renal Services has a focus on high quality patient care and pioneering use of innovative equipment and technology," says Brendan Kane, US Director of Sales at Redsense: "Their decision to deploy the Redsense system at one of their facilities is an indication of that ambition, and fits well with their specific interest in patient safety, further; we are pleased to be able to contribute to that and to the safety of their patients."
The Redsense System improves patient safety during hemodialysis by continuously monitoring the blood access site for Venous Needle Dislodgement (VND) - a potentially life-threatening complication.
"Adopting the Redsense alarm as a safety device is quickly becoming a standard practice among dialysis providers. Redsense is already supplying several of the largest providers on the market with the solution, and the growing provider SRS is a welcome addition. We are looking forward to a fruitful relationship with the Sanderling Renal Services team," saysPatrik Byhmer, CEO of Redsense Medical AB.
About Sanderling Renal Services
Sanderling Renal Services opened its first clinic in Oklahoma in 2013, and has since extended operations across the country, driven by a strong dedication to develop renal care services close to patients through remote clinical services and the establishment of smaller facilities in the proximity of underserved communities in need.
The founder, Dr. Tannenbaum, has a 30-year track-record of successful development of dialysis clinics, previously serving as founder, Chairman, and CEO of REN Corporation, National Nephrology Associates and DSI Renal - three of the largest dialysis operators in the United States. Before Sanderling's inception, DSI's clinics were acquired by DaVita, the second-largest dialysis provider in the United States; DaVita currently serves more than a third of the US patients.